CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D058186: Acute Kidney Injury NIH

(Synonyms: Acute Kid, Acute Kidn, Acute Kidney, Acute Kidney Injury)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (12)


Name (Synonyms) Correlation
drug233 Conventional treatment Wiki 0.45
drug56 Any drug used to treat Covid-19 Wiki 0.45
drug33 Aerosol-reducing Mask Wiki 0.45
drug23 ACEIs Wiki 0.45
drug27 AZ Wiki 0.45
drug329 HB-adMSC Wiki 0.45
drug127 Blood Transfusion Wiki 0.45
drug331 HC Wiki 0.45
drug30 Acalabrutinib Wiki 0.45
drug764 Standard Mask Wiki 0.45
drug37 Allogeneic NK transfer Wiki 0.45
drug616 Placebo Wiki 0.05

Correlated MeSH Terms (13)


Name (Synonyms) Correlation
D009102 Multiple Organ Failure NIH 0.45
D007049 Iatrogenic Disease NIH 0.45
D007238 Infarction NIH 0.32
D018746 Systemic Inflammatory Response Syndrome NIH 0.26
D009203 Myocardial Ischemia NIH 0.26
D014947 Wounds and Injuries NIH 0.18
D012128 Respiratory Distress Syndrome, Adult NIH 0.12
D055371 Acute Lung Injury NIH 0.07
D013577 Syndrome NIH 0.07
D012127 Respiratory Distress Syndrome, Newborn NIH 0.07
D018352 Coronavirus Infections NIH 0.05
D014777 Virus Diseases NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.03

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.45
HP:0001658 Myocardial infarction HPO 0.45

There are 5 clinical trials

Clinical Trials


1 CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)

The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).

NCT03229941 Myocardial Infarction Coronary Revascularization Acute Renal Failure Procedure: Blood Transfusion
MeSH:Acute Kidney Injury Myocardial Infarction Infarction
HPO:Acute kidney injury Myocardial infarction

Primary Outcomes

Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.

Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization.

Time: 90 days after randomization

Secondary Outcomes

Description: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.

Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis.

Time: 90 days after randomization

Description: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.

Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no

Time: 90 days after randomization

Description: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.

Measure: All-cause mortality at 1 year after randomization.

Time: 12 months after randomization

Description: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.

Measure: A composite endpoint of all-cause mortality,

Time: 30 days after randomization

Description: Length of hospital stay

Measure: Length of hospital stay.

Time: At hospital discharge, up to 1 year

Other Outcomes

Description: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure

Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint.

Time: 90 days after randomization

2 Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

NCT04314817 Coronavirus Iatrogenic Disease Acute Kidney Injury ARDS, Human Drug: Any drug used to treat Covid-19
MeSH:Coronavirus Infections Respiratory Distress Syndrome, Adult Acute Kidney Injury Iatrogenic Disease
HPO:Acute kidney injury

Primary Outcomes

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Renal failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Secondary Outcomes

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Heart failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: EKG disturbance

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Hepatic failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Anemia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Leucopenia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Vascular disease

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Toxidermia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Osteoarticular adverse event

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Death

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Acute respiratory distress syndrome

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Pulmonary embolism or pulmonary hypertension

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

3 Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study

The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.

NCT04316299 COVID-19 Acute Kidney Injury Kidney Function
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: the incidence of Acute Kidney Injury

Measure: Rate of Acute Kidney Injury

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

Secondary Outcomes

Description: death from any cause in the hospital

Measure: Rate of Death

Time: From date of admission until the date of death from any cause, up to 60 days

Description: days from admission to discharge or death

Measure: the length of hospital stay

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

4 Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

NCT04316884 COVID-19 Organ Dysfunction Syndrome Sepsis Organ Dysfunction Syndrome, Multiple Septic Shock Acute Kidney Injury Acute Respiratory Distress Syndrome
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Acute Kidney Injury Syndrome Multiple Organ Failure Systemic Inf Systemic Inflammatory Response Syndrome
HPO:Acute kidney injury

Primary Outcomes

Description: KDIGO AKI score

Measure: Acute Kidney Injury

Time: During Intensive Care, an estimated average of 10 days.

Secondary Outcomes

Description: Acute Respiratory Distress Syndrome yes/no

Measure: ARDS

Time: During intensive care, an estimated average of 10 days.

Description: Death within 30 days of ICU admission

Measure: 30 day mortality

Time: 30 days

Description: Death within 1 year of ICU admission

Measure: 1 year mortality

Time: 1 year

Description: Development of Chronic Kidney Disease

Measure: Chronic Kidney Disease

Time: 60 days and 1 year after ICU admission

Description: Sequential Organ Failure Score as a continuous variable

Measure: SOFA-score

Time: During Intensive Care, an estimated average of 10 days.

5 Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19)

Acute kidney injury (AKI) is reported to occur in 0.5-9% of severe acute respiratory distress coronavirus 2-positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of renal outcome of in-hospital patients diagnosed with COVID-19.

NCT04353583 Acute Kidney Injury Corona Virus Infection
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Acute Kidney Injury Virus Diseases
HPO:Acute kidney injury

Primary Outcomes

Description: As determined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria

Measure: Incidence of AKI

Time: Within 7 days after admission

Secondary Outcomes

Description: Serial biomarker assessment

Measure: Renal function changes during hospital stay

Time: from hospital admission til discharge up to 3 months

Description: As determined by KDIGO criteria

Measure: Incidence of chronic kidney disease

Time: 3 months post-hospital admission


HPO Nodes